Literature DB >> 11426065

Residual HIV-1 infection during antiretroviral therapy: the challenge of viral persistence.

R J Pomerantz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11426065     DOI： 10.1097/00002030-200107060-00002

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

1.  HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Authors:  Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

Review 2.  Neurologic aspects of HIV infection in infants and children: therapeutic approaches and outcome.

Authors:  Lucy Civitello
Journal:  Curr Neurol Neurosci Rep       Date:  2003-03       Impact factor: 5.081

3.  Characterization of HIV-1 RNA forms in the plasma of patients undergoing successful HAART.

Authors:  Carlos A Lopez; Manuel Vazquez; Martin D Hill; Maria Del C Colon; Tirtsa Porrata-Doria; Ian C D Johnston; Eric Lorenzo
Journal:  Arch Virol       Date:  2010-04-23       Impact factor: 2.574

4.  Evaluation of atazanavir and darunavir interactions with lipids for developing pH-responsive anti-HIV drug combination nanoparticles.

Authors:  Jinghua Duan; Jennifer P Freeling; Josefin Koehn; Cuiling Shu; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2014-06-19       Impact factor: 3.534

5.  In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months.

Authors:  Michele Di Mascio; Geethanjali Dornadula; Hui Zhang; Julie Sullivan; Yan Xu; Joseph Kulkosky; Roger J Pomerantz; Alan S Perelson
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

Review 6.  Sexually transmitted infections and HIV in the era of antiretroviral treatment and prevention: the biologic basis for epidemiologic synergy.

Authors:  Myron S Cohen; Olivia D Council; Jane S Chen
Journal:  J Int AIDS Soc       Date:  2019-08       Impact factor: 5.396
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.